diabetes treatment News
-
Defymed at the International Conference on Advanced Technologies and Treatments of Diabetes (ATTD)
Our CEO, COO and BDO (Severine, Richard and Manuel) will attend the International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) which will take place in Barcelona (Spain) from April 27th to 30th. The purpose of the ATTD meeting is to highlight innovative technologies in diabetes treatment. It brings together developers of new technologies, like us, with the diabetes ...
By Defymed
-
“High Treatment Satisfaction with 3-day Insulin Patch is Independent of Patient Demographics: A Post-Hoc Analysis” — a presentation at the American Diabetes Association 80th Scientific Sessions
Progression of Type 2 Diabetes Treatment Due to natural progression of type 2 diabetes, maintenance of glycemic targets requires a stepwise approach to treatment in order to achieve and maintain glycemic control and avoid complications1'2 Comprehensive lifestyle modifications combined with metformin Addition of up to 3 oral medications or GLP-1 RA injection Addition of basal (long-acting) ...
-
Huateng Pharma Introduces Anti-Diabetes Intermediates
Huateng Pharma proudly announces the launch of a groundbreaking suite of anti-diabetes intermediates, featuring key compounds such as Canagliflozin, Dapagliflozin, Empagliflozin, and Semaglutide. Emphasizing the potential impact on diabetes drug development, Huateng Pharma's Research and Development Director expressed enthusiasm, stating, "Our new line of anti-diabetes intermediates represents a ...
-
Defymed at ATTD 2023
22-25 February (Berlin, Germany): Defymed at the Advanced Technologies and treatments for Diabetes. The purpose of the ATTD meeting is to highlight innovative technologies and treatments in diabetes management. It brings together developers of new technologies with the diabetes professionals and caretakers, researchers, industries, startup companies, investors, reimbursement authorities and ...
By Defymed
-
Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe
Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense® NOW Remote Monitoring App for the Android Operating System. The Eversense NOW iOS platform has previously been approved and ...
By Senseonics
-
Senseonics Announces Equity Grants To Employees Under Inducement Plan
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American Company Guide Section ...
By Senseonics
-
Successful Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes
NESS ZIONA, ISRAEL, October 12, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing cell therapy treatments for ALS and diabetes, announced today that the Company held a preliminary meeting with the FDA (INTERACT) on October 7, 2021 regarding IsletRx, the company’s cell therapy product in development for the treatment of diabetes. During the meeting, ...
-
SQZ Biotechnologies Publishes Comprehensive Preclinical Research on SQZ® TAC Platform’s Ability to Induce Multiple Key Mechanisms of AntigenSpecic Tolerance and Protect Against Type 1 Diabetes
WATERTOWN, Mass.--(BUSINESS WIRE)-- SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of comprehensive preclinical research on the SQZ® Tolerizing Antigen Carrier (TAC) platform. The data, published in Frontiers in Immunology, demonstrated that TACs can induce multiple key mechanisms of ...
-
Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease
BASKING RIDGE, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the Independent Data Monitoring Committee (“IDMC”) overseeing the Phase 1b, ...
-
New training manual for treatment of type 1 diabetes in children in developing countries
In collaboration with the International Society for Pediatric and Adolescent Diabetes (ISPAD) Novo Nordisk has today launched a training manual specific to the diagnosis and treatment of diabetes care for children in developing countries. Unveiled on the opening day of the ISPAD Congress 'ISPAD 2010', which is currently taking place in Buenos Aires, this first edition of the manual is available ...
-
Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease
BASKING RIDGE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that the first patient has been treated in its Phase 1b open-label, proof-of-concept study of ...
-
Patent for Cell Selection of Beta Cells to Treat and Potentially Cure Diabetes was Granted in Japan
Ness Ziona, Israel, July, 2021 --- Cell therapy company Kadimastem Ltd (TASE: KDST) has received its patent approval from the Japanese Patent Office for IsletRx, the company’s innovative treatment for diabetes. IsletRx comprises an expanded population of clinical grade pancreatic islet-like cluster (ILCs) cells, derived from human stem cells, that have the ability to secrete insulin when ...
-
EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis
EndoLogic announced that the FDA accepted the cardiac safety trial for renzapride in patients with gastroparesis. That study demonstrated no evidence of QTc prolongation in the EKG findings. The U.S. Food and Drug Administration (FDA) views this study as sufficient to characterize renzapride’s QTc prolongation potential at both therapeutic (4 mg per day) and supra-therapeutic (20 mg per ...
-
Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR Therapeutic Procedure in Patients with Type 2 Diabetes
REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of improvements in blood glucose, weight, and broader metabolic parameters with no device- or procedure-related adverse events in long-term follow-up after a single Revita procedure ...
-
Durable Healing Outcomes of Topical Wound Oxygen (TWO2) Therapy Highlighted at Leading International Clinical Conferences
Advanced Oxygen Therapy Inc. (AOTI) announced today that its unique multimodality Topical Wound Oxygen (TWO2) therapy was recently highlighted at multiple leading international clinical conferences across the United States and United Kingdom. AOTI participated both as a sponsor and exhibitor at these events that were conducted in a hybrid format, where attendance could be either in person, or ...
-
Israeli firm says micro-pancreas to `cure` diabetes ready for UK trials
Exclusive: hopes testing can begin in 2021 on product intended to free people of need for insulin injections An Israeli company claiming to have created a tiny micro-pancreas that can “cure” diabetes for millions of people has said it will submit a request next month for human clinical trials in the UK. Betalin Therapeutics said its “bio-artificial” pancreas aims to ...
-
Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins
Protease inhibitor is a key component of Oramed’s PODTM technology that protects therapeutic proteins in the digestive system Oramed has already been granted this patent in the United States and Japan Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the ...
-
Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy
REDWOOD CITY, Calif., Jan. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that UnitedHealthcare, the largest private health insurance company in the United States, will provide coverage for the company's high-frequency 10 kHz Therapy for the treatment of ...
By Nevro Corp.
-
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes
Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd. ("Biolojic"), a biotechnology company that computationally designs functional antibodies, today announced a research collaboration and license agreement that will leverage Biolojic's AI-based multibody platform to discover and develop a potential novel antibody-based therapy for the treatment of diabetes. A multi-specific antibody, or ...
-
Alkahest Announces Initiation of Phase 2b Clinical Trial of AKST4290 in Patients with Treatment-Naïve Wet Age-Related Macular Degeneration
Alkahest, Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first subject in AKST4290-205 (PHTHALO), which will assess the effects of AKST4290 on visual ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you